These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31057354)

  • 1. Polymorphisms in Dopaminergic Genes in Schizophrenia and Their Implications in Motor Deficits and Antipsychotic Treatment.
    Ye J; Ji F; Jiang D; Lin X; Chen G; Zhang W; Shan P; Zhang L; Zhuo C
    Front Neurosci; 2019; 13():355. PubMed ID: 31057354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
    Segman RH; Heresco-Levy U; Finkel B; Goltser T; Shalem R; Schlafman M; Dorevitch A; Yakir A; Greenberg D; Lerner A; Lerer B
    Mol Psychiatry; 2001 Mar; 6(2):225-9. PubMed ID: 11317227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Variants Within Key Nodes of the Cascade of Antipsychotic Mechanisms: Effects on Antipsychotic Response and Schizophrenia Psychopathology in a Naturalistic Treatment Setting in Two Independent Korean and Italian Samples.
    Calabrò M; Porcelli S; Crisafulli C; Wang SM; Lee SJ; Han C; Patkar AA; Masand PS; Albani D; Raimondi I; Forloni G; Bin S; Mattiaccio A; Mantovani V; Jun TY; Pae CU; Serretti A
    Adv Ther; 2017 Jun; 34(6):1482-1497. PubMed ID: 28508933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.
    Tybura P; Samochowiec A; Beszlej A; Grzywacz A; Mak M; Frydecka D; Bieńkowski P; Mierzejewski P; Potemkowski A; Samochowiec J
    Pharmacol Rep; 2012; 64(3):528-35. PubMed ID: 22814006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
    Tybura P; Trześniowska-Drukała B; Bienkowski P; Beszlej A; Frydecka D; Mierzejewski P; Samochowiec A; Grzywacz A; Samochowiec J
    Psychiatry Res; 2014 Oct; 219(2):261-7. PubMed ID: 24930580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients.
    Zhou W; Xu Y; Lv Q; Sheng YH; Chen L; Li M; Shen L; Huai C; Yi Z; Cui D; Qin S
    Front Pharmacol; 2019; 10():177. PubMed ID: 30886581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics and antipsychotic treatment response.
    Naumovska Z; Nestorovska AK; Filipce A; Sterjev Z; Brezovska K; Dimovski A; Suturkova LJ
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):53-67. PubMed ID: 26076775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val¹⁰⁸/¹⁵⁸Met polymorphism, gender and symptomatology.
    Boot E; Booij J; Abeling N; Meijer J; da Silva Alves F; Zinkstok J; Baas F; Linszen D; van Amelsvoort T
    J Psychopharmacol; 2011 Jul; 25(7):888-95. PubMed ID: 21447540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of schizophrenia adverse drug interactions through a network approach and drug classification.
    Sun J; Zhao M; Fanous AH; Zhao Z
    Biomed Res Int; 2013; 2013():458989. PubMed ID: 24089679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder.
    Mehler-Wex C; Riederer P; Gerlach M
    Neurotox Res; 2006 Dec; 10(3-4):167-79. PubMed ID: 17197367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis-Based Preliminary Exploration of the Connection between ATDILI and Schizophrenia by GSTM1/T1 Gene Polymorphisms.
    Cai L; Cai MH; Wang MY; Xu YF; Chen WZ; Qin SY; Wan CL; He L
    PLoS One; 2015; 10(6):e0128643. PubMed ID: 26046920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases.
    Sundararajan T; Manzardo AM; Butler MG
    Gene; 2018 Jan; 641():25-34. PubMed ID: 29032150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.
    Zivković M; Mihaljević-Peles A; Bozina N; Sagud M; Nikolac-Perkovic M; Vuksan-Cusa B; Muck-Seler D
    J Clin Psychopharmacol; 2013 Oct; 33(5):593-9. PubMed ID: 23963056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms of serotonin neurotransmission and their effects on antipsychotic drug action.
    Tang H; McGowan OO; Reynolds GP
    Pharmacogenomics; 2014; 15(12):1599-609. PubMed ID: 25340734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms.
    Srivastava V; Varma PG; Prasad S; Semwal P; Nimgaonkar VL; Lerer B; Deshpande SN; BK T
    Pharmacogenet Genomics; 2006 Feb; 16(2):111-7. PubMed ID: 16424823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
    Arranz MJ; de Leon J
    Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia.
    Terzić T; Kastelic M; Dolžan V; Plesničar BK
    Psychiatr Danub; 2016 Jun; 28(2):127-31. PubMed ID: 27287786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.
    Greenbaum L; Lerer B
    Front Neurol; 2015; 6():27. PubMed ID: 25750634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-Edged Sword of Tumour Suppressor Genes in Schizophrenia.
    Zhuo C; Wang D; Zhou C; Chen C; Li J; Tian H; Li S; Ji F; Liu C; Chen M; Zhang L
    Front Mol Neurosci; 2019; 12():1. PubMed ID: 30809121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.
    Calabrò M; Porcelli S; Crisafulli C; Wang SM; Lee SJ; Han C; Patkar AA; Masand PS; Albani D; Raimondi I; Forloni G; Bin S; Cristalli C; Mantovani V; Pae CU; Serretti A
    J Mol Neurosci; 2018 Jan; 64(1):62-74. PubMed ID: 29164477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.